Plasma #hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma.
Biodena Care
Access to quality care must not remain a privilege. L'accès à des soins de qualité ne doit pas rester un privilège.
It’s a great pleasure to share with you our last publication showing Plasma #hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma.
Liver cancer is the sixth most common cancer world-wide and hepatocellular carcinoma (HCC), the most common form of primary liver cancer, accounts for 90% of the cases.
?The diagnosis of HCC is usually based on abdominal ultrasonography or high serum alpha-fetoprotein (AFP) levels. However, as it is only elevated in 60% of patients with HCC, AFP has limited accuracy, especially in early stages, as both a diagnostic and prognostic test. ??
We found that hPG80 levels is both an independent prognostic marker in HCC and used in combination with AFP, it improves the stratification of the patients in good and poor prognosis, especially for those patients at early-stage.
?This will help stratify #HCC patients more accurately in the future and improve the management of these patients.
?Thanks to Eric Assenat from CHU de Montpellier and his team for this great collaboration.
?